UCB SA Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of UCB SA Insights data

Headline Published Journalists
Showing 3 of 90+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 28 Jul 2021 Lorem
Zogenix’s fenfluramine uptake inertia expected in Dravet syndrome with entrenched competitor, though differentiated MOA provides some edge, experts say 24 Jan 2020 Shuan Sim
UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year, exec says 26 Sep 2019 Shuan Sim
Engage Therapeutics will welcome CRO approaches for Phase III epilepsy trial in 1H20; early 2020 topline data to open doors for partnering talks, CEO says 12 Jul 2019 Shuan Sim
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward